Inhibikase Therapeutics (IKT) Competitors $2.64 +0.11 (+4.35%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends IKT vs. JATT, MGX, ZIVO, OMGA, ENTX, CDTX, DTIL, CVM, BLUE, and QNCXShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include JATT Acquisition (JATT), Metagenomi (MGX), ZIVO Bioscience (ZIVO), Omega Therapeutics (OMGA), Entera Bio (ENTX), Cidara Therapeutics (CDTX), Precision BioSciences (DTIL), CEL-SCI (CVM), bluebird bio (BLUE), and Quince Therapeutics (QNCX). These companies are all part of the "biological products, except diagnostic" industry. Inhibikase Therapeutics vs. JATT Acquisition Metagenomi ZIVO Bioscience Omega Therapeutics Entera Bio Cidara Therapeutics Precision BioSciences CEL-SCI bluebird bio Quince Therapeutics Inhibikase Therapeutics (NYSE:IKT) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends. Does the media prefer IKT or JATT? In the previous week, Inhibikase Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for JATT Acquisition. Inhibikase Therapeutics' average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score. Company Overall Sentiment Inhibikase Therapeutics Neutral JATT Acquisition Neutral Does the MarketBeat Community favor IKT or JATT? Inhibikase Therapeutics received 8 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformInhibikase TherapeuticsOutperform Votes888.89% Underperform Votes111.11%JATT AcquisitionN/AN/A Which has preferable earnings & valuation, IKT or JATT? JATT Acquisition has lower revenue, but higher earnings than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K75.75-$19.03M-$2.88-0.92JATT AcquisitionN/AN/A$6.85MN/AN/A Do institutionals and insiders hold more shares of IKT or JATT? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 14.7% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is IKT or JATT more profitable? JATT Acquisition's return on equity of -49.58% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -194.17% -140.64% JATT Acquisition N/A -49.58%2.84% Do analysts rate IKT or JATT? Inhibikase Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 89.39%. Given Inhibikase Therapeutics' higher possible upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryInhibikase Therapeutics and JATT Acquisition tied by winning 5 of the 10 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$19.69M$3.15B$5.54B$19.25BDividend YieldN/A1.77%5.13%3.53%P/E Ratio-0.9211.73114.8141.38Price / Sales75.75397.851,495.5514.64Price / CashN/A148.6639.6720.86Price / Book1.484.024.665.39Net Income-$19.03M-$42.25M$119.06M$985.39M7 Day Performance9.09%8.04%0.80%-0.71%1 Month Performance106.25%8.69%5.65%-0.97%1 Year Performance144.44%32.09%36.75%25.05% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics2.2907 of 5 stars$2.64+4.3%$5.00+89.4%+210.6%$19.69M$260,000.00-0.928JATTJATT AcquisitionN/A$4.48-2.8%N/A-6.8%$77.28MN/A0.003High Trading VolumeMGXMetagenomi2.4594 of 5 stars$1.99-0.5%$15.50+678.9%N/A$74.86M$55.93M0.00236ZIVOZIVO BioscienceN/A$19.95flatN/A+712.5%$69.63M$30,000.00-3.7910Positive NewsOMGAOmega Therapeutics1.4332 of 5 stars$1.24-2.4%$10.20+722.6%-17.8%$68.39M$3.09M-0.87120ENTXEntera Bio2.8986 of 5 stars$1.89+1.6%$10.00+429.1%+170.4%$67.63M$57,000.00-7.2720Short Interest ↓Positive NewsGap UpCDTXCidara Therapeutics4.2841 of 5 stars$13.39+7.4%$29.67+121.6%-18.5%$61.09M$53.87M-0.5490Upcoming EarningsNews CoverageDTILPrecision BioSciences4.0258 of 5 stars$8.16-1.4%$39.50+384.1%-24.6%$59.03M$87.64M39.25200Upcoming EarningsCVMCEL-SCIN/A$0.91-1.1%N/A-47.5%$58.68MN/A-1.5743BLUEbluebird bio2.8541 of 5 stars$0.49flat$4.63+842.1%-84.1%$53.77M$54.90M-0.22323Upcoming EarningsAnalyst ForecastQNCXQuince Therapeutics3.221 of 5 stars$1.18+19.2%$11.00+832.2%+59.4%$50.99MN/A-0.9460Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies JATT Alternatives MGX Alternatives ZIVO Alternatives OMGA Alternatives ENTX Alternatives CDTX Alternatives DTIL Alternatives CVM Alternatives BLUE Alternatives QNCX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:IKT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
